Takeda walks away from cell therapy in priority U-turn
The pharma will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio prioritisation”.
03 October 2025
03 October 2025
The pharma will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio prioritisation”.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.